5 Notable Drug Name Changes
Brintellix isn't the only drug that underwent a brand name change in order to curb confusion with another drug.
Brintellix isn’t the only drug that underwent a brand name change in order to
The FDA recently announced that the brand name of the antidepressant Brintellix has been changed to Trintellix in order to avoid
Pharmacy Times’ Facebook followers
1. Losec Changed to Prilosec
Shortly after the launch of the proton pump inhibitor Losec (omeprazole) in 1989, reports of confusion with the diuretic Lasix (furosemide)
2. Celebra Changed to Celebrex
G.D. Searle originally chose the name Celebra (celecoxib) for its blockbuster arthritis drug, but then a pharmacy professor complained that it sounded too similar to Forest Laboratories’ antidepressant Celexa. The FDA agreed, and so Celebra was changed to Celebrex.
3. Reminyl Changed to Razadyne
The brand name of Ortho-McNeil Neurologics’ Alzheimer’s drug Reminyl (galantamine HBr) was changed to Razadyne
Ortho-McNeil Neurologics worked closely with the FDA about necessary actions upon learning of several reports of prescribing and dispensing errors between Reminyl and Amaryl. In 2 cases, patients with Alzheimer’s disease were given Amaryl, which resulted in their deaths.
4. Kapidex Changed to Dexilant
Takeda Pharmaceuticals North America Inc announced in March 2010 that Kapidex (dexlansoprazole) would be marketed as
The product is indicated for heartburn associated with symptomatic nonerosive gastroesophageal reflux disease, the healing of erosive esophagitis (EE), and the maintenance of healed EE.
5. Omacor Changed to Lovaza
Reliant Pharmaceuticals announced on August 3, 2007, that the brand name of Omacor was changed to
Lovaza is indicated as an adjunct to diet to reduce very high (greater than or equal to 500 mg/dL) triglyceride levels in adult patients. In individuals with hypertriglyceridemia, excess body weight and excess alcohol intake may be important contributing factors and should be addressed before initiating any drug therapy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025